Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Feng, Daofu ^a,b   Leong, Meiha ^a,c   Li, Ting ^a   Chen, Lin ^a   Li, Tao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Macao Special Administrative Region of the People's Republic of China   (Macao)

Author keywords

Complications; D2 lymphadenectomy; Gastric cancer; Neoadjuvant chemotherapy; Pathological complete response

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DRUG COMBINATION; FLUOROURACIL; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ABDOMINAL ABSCESS; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BILE DUCT FISTULA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CATHETER; CATHETER INFECTION; CLINICAL TRIAL; DRUG DOSE REDUCTION; FEMALE; GASTRECTOMY; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; KIDNEY DYSFUNCTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS FISTULA; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE ILEUS; RETROSPECTIVE STUDY; STOMACH CANCER; STOMACH PARESIS; SURGICAL INFECTION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; WOUND DEHISCENCE; ADJUVANT CHEMOTHERAPY; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; STOMACH NEOPLASMS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84924156454     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0444-6     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortalities from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortalities, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50.
4. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009;10:903-12.
5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
7. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-96.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
9. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
10. Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007;13:168-74.
11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takaqi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
12. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423-8.
13. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2013. doi:10.1007/s10120-013-0297-z
14. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 2010;21:1001-5.
15. Liu B, Ying J, Luo C, Xu Q, Zhu L, Zhong H. S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. Hepatogastroenterology. 2012;59:649-53.
16. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Suqimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; Oct 14. doi:10.1093/annonc/mdu472.
17. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518-26.
18. SOX regimen as neoadjuvant chemotherapy for AJCC stage II-III gastric cancer (RESONANCE), ClinicalTrials.gov, (Identifier: NCT01583361).
19. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. Third English edition. Gastric Cancer. 2011;14:101-12.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
21. Yano M, Tsujinaka T, Shiozaki H, Inoue M, Sekimoto M, Doki Y, et al. Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World J Surg. 2000;24:1130-6.
22. Nam DH, Lee YK, Park JC, Lee H, Shin SK, Lee SK, et al. Prognostic value of early postoperative tumor marker response in gastric cancer. Ann Surg Oncol. 2013;20:3905-11.
23. Li ZY, Shan F, Zhang LH, Bu ZD, Wu AW, Zong XL, et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol. 2011;9:110.
24. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51.
25. Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol. 2012;105:535-41.
26. Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643-9.
27. de Díaz LA, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008;11:96-102.
28. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
29. Sasako M, for the Dutch Gastric Cancer Study Group. Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg. 1997;84:1567-71.
30. Lang H, Piso P, Stukenborg C, Raab R, Jahne J. Management and results of proximal anastomotic leaks in a series of 1114 total gastrectomies for gastric carcinoma. Eur J Surg Oncol. 2000;26:168-71.
31. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015-22.
32. Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS Trial. Ann Surg Oncol. 2014;21:213-9.
33. Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sum SJ, et al. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2010;65:473-80.
34. Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho S, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs. 2012;30:350-6.
35. Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, et al. Phase II study of neoadjuvant chemotherapy with S-1 and CDDP in patients with lymph node metastatic stage II or III gastric cancer. Am J Clin Oncol. 2014; Mar 21. (PMID: 24662266).
36. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30.